Analyst Price Targets — LIVN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| September 2, 2026 10:44 am | — | Piper Sandler | $90.00 | $80.16 | TheFly | LivaNova price target raised to $90 from $87 at Piper Sandler |
| August 5, 2026 5:55 pm | — | Stifel Nicolaus | $85.00 | $76.59 | TheFly | LivaNova price target raised to $85 from $80 at Stifel |
| August 5, 2026 5:14 pm | — | Needham | $93.00 | $76.59 | TheFly | LivaNova price target raised to $93 from $81 at Needham |
| July 15, 2026 11:26 am | — | Mizuho Securities | $95.00 | $79.12 | TheFly | LivaNova price target raised to $95 from $90 at Mizuho |
| June 22, 2026 9:44 am | — | KeyBanc | $92.00 | $78.50 | TheFly | LivaNova price target raised to $92 from $83 at KeyBanc |
| May 7, 2026 11:15 am | — | Mizuho Securities | $90.00 | $66.26 | TheFly | LivaNova price target raised to $90 from $85 at Mizuho |
| May 7, 2026 9:33 am | — | Barclays | $76.00 | $66.26 | TheFly | LivaNova price target raised to $76 from $73 at Barclays |
| February 25, 2026 8:54 pm | — | Stifel Nicolaus | $80.00 | $70.29 | TheFly | LivaNova price target raised to $80 from $70 at Stifel |
| February 25, 2026 5:09 pm | Mike Matson | Needham | $81.00 | $70.29 | StreetInsider | Livanova (LIVN) PT Raised to $81 at Needham |
| February 19, 2026 1:24 pm | Adam Maeder | Piper Sandler | $85.00 | $67.33 | StreetInsider | Piper Sandler on Livanova (LIVN): 'Favorite SMID Value Name On Our List' |
Latest News for LIVN
Bank of America Corp DE cut its holdings in shares of LivaNova PLC (NASDAQ: LIVN) by 30.6% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 533,017 shares of the company's stock after selling 235,233 shares during the quarter. Bank of America Corp
LivaNova (NASDAQ: LIVN - Get Free Report) and Dynatronics (NASDAQ: DYNT - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk. Risk and Volatility LivaNova has a beta of 0.86, indicating
LIVN's Q2 earnings and revenues beat estimates as Cardiopulmonary and Epilepsy growth fuels margin gains and a raised 2026 outlook.
LivaNova PLC (LIVN) Q2 2026 Earnings Call Transcript
LivaNova NASDAQ: LIVN reported record quarterly revenue and adjusted earnings per share for the second quarter of 2026, citing double-digit reported growth across its Cardiopulmonary and Epilepsy businesses. The company raised its full-year revenue and adjusted EPS outlook while reducing its adjusted free-cash-flow forecast to account for increased investment in manufacturing capacity, innovation and IT…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for LIVN.
U.S. House Trading
No House trades found for LIVN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.